General Updates

16th July, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East , Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”). Dear Sir(s)/ Madam, Pursuant to Regulation 30 of the SEBI LODR Regulations, this is to inform you that the Company has acquired 79,36,50,794 equity shares at issue price of Rs. 13.86 per equity share aggregating to Rs. 11,00,00,00,005/- (‘Rights Shares’) offered by Alkem Medtech Private Limited, a wholly owned subsidiary of the Company in India (“Alkem Medtech”), on a rights basis. The Company has been allotted aforesaid Rights Shares by Alkem Medtech on 15th July, 2026. In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026, have been provided in Annexure – I. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations. Request you to kindly take the same on record. Sincerely, For Alkem Laboratories Limited Manish Narang President – Legal, Company Secretary & Compliance Officer Encl: a/a Annexure I Particulars Remarks Name of the target entity, details in brief such as Alkem Medtech Private Limited, a wholly owned size, turnover etc.: subsidiary of the Company (“Alkem Medtech”) in India having a turnover of INR 15.13 crores for the financial year ended 31st March, 2026. Whether the acquisition would fall within related Acquisition does not fall within the purview of party transaction(s) and whether the related party transaction. promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “Arms-length” Industry to which the entity being acquired Medical Device belongs Objects and impact of acquisition (including but To acquire at least 51% and up to 55% of the total not limited to, disclosure of reasons for issued equity share capital of M/s. Occlutech acquisition of target entity, if its business is Holding AG. outside the main line of business of the listed entity) Brief details of any governmental or regulatory Not Applicable approvals required for the acquisition Indicative time period for completion of the Equity shares were allotted on 15th July, 2026. acquisition Consideration- whether cash consideration or Cash consideration. share swap and details of the same Cost of acquisition or the price at which the Rs. 11,00,00,00,005/- shares are acquired; 79,36,50,794 equity shares at issue price of Rs. 13.86 per equity share. Percentage of shareholding / control acquired Alkem Medtech is a wholly owned subsidiary and/or number of shares acquired; of the Company in India. Number of shares acquired : 79,36,50,794 equity shares at issue price of Rs. 13.86 per equity share. Brief background about the entity acquired in Alkem Medtech was incorporated on 27th March, terms of products/line of business acquired, date 2024 under the provisions of the Companies Act, of incorporation, history of last 3 years turnover, 2013. It is engaged in the business of medical country in which the acquired entity has presence device segment mainly in the cardiovascular and and any other significant information (in brief); orthopedic fields. Turnover details: FY 2025-2026: INR 15.13 crores FY 2024-2025: INR NIL